LDS/Medical Tests/Oxymorphone, Urine

Oxymorphone, Urine

Oxymorphone is a semisynthetic opioid agonist derived from thebaine. Oxymorphone is much more potent than morphine. Oxymorphone is also a metabolite of oxycodone and is responsible for much of the analgesic efficacy of oxycodone. Typical routes of administration include oral, subcutaneous, intramuscular, and intravenous. Oral bioavailability is estimated at only 10%. Oxymorphone is metabolized to noroxymorphone, 6-oxymorphol, and several glucuronide conjugates. The half-life of oxymorphone is 4-12 hours.

Approximately 49% of a single oral dose is eliminated in the urine within 5 days. Actual elimination depends on factors such as drug formulation dose, dose frequency, clinical status and pharmacokinetics of the individual patient.

Common side effects: respiratory depression, sedation, nausea, vomiting, dizziness, headache, fever, miosis, constipation, urinary retention, and pruritis. Oxymorphone can also contribute to the following effects: hypotension, bradycardia, euphoria, mental clouding, amnesia, hostility, irritability, and vivid or disturbing dreams. Can be addictive. Overdose effects include apnea, circulatory collapse, cardiac arrest, coma, and possible death.

Oxymorphone and metabolites can be detected in urine by a variety of analytical methods (see below); both qualitative and quantitative tests are available.

  • Adherence monitoring
  • Drug abuse evaluation
  • Toxicity/Overdose assessment
A qualitative positive result indicates only the presence of Oxymorphone and does not necessarily correlate with the extent of physiological and psychological effects, nor does it predict the dose that was taken or administered. Any result that is inconsistent with clinical expectations should be confirmed or quantitated by a second method.

Therapeutic Level: 10-100 ng/mL
Toxic level: >200 ng/mL

Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration are preferred for pharmacokinetic analyses.

Cut-Off Ranges:
Cut-off values are used to determine the positivity of the urine specimen being analyzed. Cut-off values can vary based on the particular method of analysis that is used for detection, or laboratory, whether the test is a qualitative method or a quantitative method. Detection will be improved with low cutoff concentrations. The testing laboratory cut-off range is listed on the patient report.

Liquid Chromatography/Mass Spectroscopy (LC/MS, LC-MS/MS), Gas Chromatography/Mass Spectroscopy (GC/MS), or Thin Layer Chromatography (TLC). Immunoassays for opiates or oxycodone are generally not sensitive to oxymorphone or oxymorphone metabolites. Targeted assays can distinguish between oxymorphone and major metabolites such as noroxymorphone, and the glucuronide conjugates. Many laboratories include a pre-analytical hydrolysis reaction to liberate the glucuronide conjugates, which may improve detection.

Fresh urine specimen collected in either a clean glass or plastic container. An acceptable urine specimen (random) submitted for testing should be in the pH range of 3-11. Creatinine or specific gravity results will identify dilute specimens. Adulteration of the urine specimen can result in erroneous results.

Stability

  • Ambient: 3-5 days
  • Refrigeration: 5-7 days
  • Frozen: 30 days
Pharmacogenetic testing such as genotyping for *CYP3A4, CYP3A5, CYP2D6, CYP2C9, CYP2C19,* and *OPRM1* variants could guide drug and dose selection. Supportive testing such as a liver profile, kidney profile, comprehensive metabolic panel, CBC, and testing for concomitant drugs may be appropriate.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 9th ed. Foster City, CA: Biomedical Publications; 2011.
  • Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 6th ed. Foster City, CA: Biomedical Publications; 2002.
  • Levine B (ed). Miscellaneous Central Nervous System Depressants. In: Principles of Forensic Toxicology, 4th Ed. Washington DC: AACC Press; 2013:261-270.
  • Brunton LL, Chabner B, Knollman B (eds). Goodman and Gilmans’ the pharmacological basis of therapeutics, 12th ed. New York: McGraw-Hill; 2010.
  • Katzung BG, Masters S, Trevor AK (eds). Basic and clinical pharmacology, 12th ed. New York: McGraw-Hill; 2011.